Navigation Links
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:7/20/2009

--- B (n=8) 50 mg/day -0.69 1 ------ ------------ ----- --- C (n=8) 75 mg/day -0.70 2 ------ ------------ ----- --- D (n=9) 100 mg/day -0.74 4 ------ ------------ ----- --- Control Placebo (n=8) +0.01 0 * Eight subjects were randomized to this cohort, two of whom were excluded from the viral load evaluation due to an error in dosing.

"We are pleased with the results of this study, which support the potential for IDX184 to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and tolerability, coupled with a low once-daily dose," said Douglas Mayers, M.D., chief medical officer of Idenix. "Now that we have successfully completed the proof-of-concept study in HCV-infected patients, we plan to advance IDX184 into a 14-day dose-ranging study in combination with the current standard-of-care, pegylated interferon and ribavirin, to determine the optimal IDX184 doses to advance into broader clinical trials."

In the 75 and 100 mg/day cohorts, patients receiving IDX184 experienced improvements in two key markers of liver injury, with mean AST and ALT levels decreasing to below the upper limit of normal. These improvements were sustained for up to 6 days post-dosing, and most levels returned to baseline 14 days post-treatment.

"We have made great progress in our HCV discovery and development programs this year," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "With the successful completion of the proof-of-concept study for IDX184 and plans to file investigational new drug applications in the coming
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article ... changes color when subjected to an impact force that is great enough to cause ... helmets or other sporting equipment so that coaches or officials would instantly see if ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed an Essure® ... , Schmidt National Law Group, a leading firm in mass-tort litigation, has filed a ... Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have been caused ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today that ... of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , ... the consumer goods industry, it can be difficult for companies to navigate, stay ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the ... couples to explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general ... Four Seasons Resort Maui, the island’s only Forbes Five Star resort and Travel + ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... the creators of the leading exergaming ,Brand ... expand the exergaming market ... 17 iTech Fitness Inc.,( http://www.iTechFitness.com ), creators of ... the signing of the 50th XRKade,location in North America ...
... Parks Associates, leading analysts will,explore the implications of ... in homes as a kickoff to CONNECTIONS(TM): The,Digital ... Roundtable: Top Trends to Watch, Tuesday, June 24,will ... focus on trends in,broadband and access services, video ...
... may be ,magic bullet, to help miilions of ... 17 (HealthDay News) -- A new compound that may ... been discovered by researchers at the University of Texas ... may prove especially important for developing countries, where diarrhea ...
... in German . , It is well-known that ... the industrial nations and, it is also well-known that it ... and the economy. In the period of just one year, ... with scientists from the Institute for Community Medicine of the ...
... primary care physicians,Novartis earns the highest sales rep ... according to new,research from TNS Healthcare. Novartis also ... ability to build strong physician relationships.,Though Pfizer also ... variability in Europe, while Merck,s European performance lags,behind ...
... in Supporting,Progressive, Financially Sound and Effective Healthcare Solutions, ... Blue and Yellow Ribbons on,June 19, NASHVILLE, ... patients in Tennessee to have ready access to ... Bredesen, for the,second consecutive year, has declared June ...
Cached Medicine News:Health News:XRKade Signs 50th Location in North America and Announces Expansion Plans 2Health News:Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM) 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:Socio-demographic factors influence costs of back pain 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4Health News:Governor Bredesen Declares Tennessee Patient Advocacy Day to Promote Healthcare Accessibility for All 2Health News:Governor Bredesen Declares Tennessee Patient Advocacy Day to Promote Healthcare Accessibility for All 3
0.25 mm diameter textured tip with protective guard....
... design has been carefully considered with both the ... ensures the optimum viewing angle and the largest ... aligned for perfect focus where it is needed ... This along with Keeler's wide angle light ...
A full function instrument at an economical price....
... The ophthalmoscope with superior aspherical optics. ... by means of the aspherical optical system ... Beta 200 allows you to view the ... retina even with a small pupil. Conventional ...
Medicine Products: